Viking Therapeutics Stock Surges on Acquisition Speculation

Shares of Viking Therapeutics experienced a substantial rally on Friday, climbing 8.1% as investor enthusiasm built around the company’s potential as a takeover target. The broader biotechnology sector is currently gripped by merger fever, with Viking emerging as a central figure in speculation concerning potential billion-dollar transactions.

The catalyst for this upward movement occurred on Thursday when Novo Nordisk revealed its plan to acquire Akero Therapeutics, a direct competitor in the MASH liver disease treatment segment. This announcement not only propelled Akero’s stock significantly higher but also ignited a widespread rally across biotechnology companies with similar developmental pipelines.

Viking Therapeutics benefited immediately from this sector-wide momentum, posting gains of approximately 5% on Thursday before extending those advances into Friday’s... Read more...